• About
    • About Sutro
    • Leadership
      • Leadership Team
      • Functional Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
    • Corporate Presentation
  • Clinical Trials & CUA
    • Clinical Trials
    • Patient Resources
    • Commitment To Patients
    • Compassionate Use Access
  • Technology
    • iADCs & Antibody-Drug Conjugates
    • XpressCF+®
    • cGMP Facility
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Pipeline
  • News
    • News Releases
    • Clinical / Scientific Presentation & Publication Highlights
    • Events
    • Events Audio Replays
  • Careers and Culture
    • The Way We Work
    • Join Our Team
    • DEIB
      • DEIB Newsletter
    • Internships
    • Sutroites
    • Volunteer
      • Current Volunteer Newsletter
  • Contact Us

Dr. Wendel Naumann of The Levine Cancer Institute, Virtual Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020

News, Presentations

Dr. Wendel Naumann of The Levine Cancer Institute, Virtual Presentation of STRO-002 Antibody-Drug Conjugate (ADC) at the American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 Dr. Wendel Naumann of The Levine Cancer Institute,...

Sutro Biopharma to Host Analyst and Investor Conference Call April 27, 2020 – PowerPoint Presentation

Events, News, Presentations

Sutro Biopharma to Host Analyst and Investor Conference Call April 27, 2020 – PowerPoint Presentation Download Presentation CLICK HERE Download...

Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer

Events, News, Presentations, Press Releases

Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer –...

American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 – STRO-002 Abstract

News, Presentations

American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 – STRO-002 Abstract STRO-002-GM1, a first in human, phase 1 Study of STRO-002, an anti-Folate Receptor alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced...

Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate

Events, News, Presentations, Press Releases

Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate -Company to present updated STRO-002 data at AACR Virtual Annual Meeting – SOUTH SAN FRANCISCO, Calif., April 20, 2020 – Sutro...
« Older Entries
Next Entries »

Sutro Biopharma

310 Utah Ave
Suite 150
South San Francisco, CA 94080
650.392.8412

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080
Phone: 650-881-6500
Fax: 650-553-9659

Google Map

Tweets by @sutrobio

Contact Us

General Inquires: general@sutrobio.com
Business Inquires: busdev@sutrobio.com
Investor Relations Inquires: IR@sutrobio.com
Careers: jobs@sutrobio.com

Copyright © 2022 Sutro Biopharma, Inc. South San Francisco, California, U.S.A.
Privacy Policy
  • Follow
  • Follow
  • Follow
Sign Up for Email Alerts